NovaBay Pharmaceuticals, Inc. (NBY) Announces Presentation Of Positive Data From Its Clinical Trial Of Auriclosene Irrigation Solution For Urinary Catheter Encrustation And Blockage
5/20/2014 9:59:24 AM
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a clinical-stage biopharmaceutical company developing non-antibiotic, topical antimicrobial products, today announced that Todd A. Linsenmeyer, M.D., Director of Urology, Kessler Institute for Rehabilitation, West Orange, NJ, and one of the principal investigators of a multi-center clinical study, will present results showing significant benefits from a new catheter irrigation solution. In the trial, 9 of 14 catheters collected from patients that irrigated twice a week with saline solution, the only current treatment option, became completely encrusted. In contrast, none of those treated with a new investigational product called Auriclosene Irrigation Solution (AIS) became significantly encrusted. Parallel reductions were seen in clinical catheter blockages.
Help employers find you! Check out all the jobs and post your resume.
comments powered by